1. CD4+CD25+ lymphocyte subsets in chronic graft versus host disease patients undergoing extracorporeal photochemotherapy
- Author
-
Paolo Sbano, G. De Aloe, Massimiliano Risulo, Pietro Rubegni, Gabriele Cevenini, Giuseppe Marotta, M. Fimiani, M. R. Carcagnì, M.G. Perari, and G D'Ascenzo
- Subjects
Adult ,CD4-Positive T-Lymphocytes ,Male ,medicine.drug_class ,education ,Immunology ,Drug Resistance ,Graft vs Host Disease ,Physical examination ,03 medical and health sciences ,fluids and secretions ,0302 clinical medicine ,Refractory ,T-Lymphocyte Subsets ,medicine ,Immunology and Allergy ,Humans ,IL-2 receptor ,Lymphocyte Count ,Receptor ,Image Cytometry ,Pharmacology ,Analysis of Variance ,medicine.diagnostic_test ,business.industry ,Anticoagulant ,Interleukin-2 Receptor alpha Subunit ,Middle Aged ,medicine.disease ,CD4 Lymphocyte Count ,Graft-versus-host disease ,Phenotype ,Treatment Outcome ,Blood chemistry ,030220 oncology & carcinogenesis ,Photopheresis ,Chronic Disease ,Population study ,Female ,Steroids ,business ,030215 immunology - Abstract
Extracorporeal photochemotherapy (ECP) has been used successfully for the treatment of chronic Graft versus Host Disease (cGvHD). However, the mechanism by which ECP exerts its protective effects remains elusive. Some recent observations have suggested a possible role of certain subsets of T lymphocytes with immunosuppressive properties (T-regulatory cells) that coexpress CD4 and high levels of the interleukin-2 receptor chain: CD4+CD25+ T lymphocytes. We studied whether ECP affects the percentage of these cells in the peripheral blood of patients with cGvHD. The study population consisted of 14 patients with cGvHD refractory to systemic steroids. On enrolment in each cycle of ECP, patients underwent clinical examination, blood chemistry analysis and other instrumental procedures to document and assess involvement of the various organs and systems. For cytofluorimetric identification and phenotyping of CD4+CD25+ T lymphocytes, peripheral blood samples were collected in EDTA anticoagulant before ECP, after 48 hours, and after 6 and 12 months from the start of treatment. The 14 patients in this study received a total of more than 300 cycles of ECP, with only minor side effects. The clinical outcome was negative in 2 patients and positive in 12 patients. Within-subject analysis indicated that the percentage of CD4+CD25+ T lymphocytes before ECP and after 12 months of treatment was significantly increased. Our study confirms that changes in the percentage of CD4+CD25+ T cells induced by ECP could be a central aspect in the cascade of immune events leading to the immunological and clinical effects of this treatment in patients with cGvHD.
- Published
- 2007